Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for BioXcel Therapeutics, Inc. (BTAI : NSDQ)

• Company Description    BioXcel Therapeutics Inc. is a clinical stage biopharmaceutical company. It focuses on drug development which utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company's product portfolio include BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. BioXcel Therapeutics Inc. is based in the United States. Number of Employees: 89

• Price / Volume Information    Yesterday's Closing Price: $13.57 Daily Weekly Monthly 20 Day Moving Average: 569,121 shares Shares Outstanding: 27.99 (millions) Market Capitalization: $379.76 (millions) Beta: 1.31 52 Week High: $39.00 52 Week Low: $9.08 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -0.80% 8.61% 12 Week -24.90% -15.60% Year To Date -33.25% -18.45%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 555 LONG WHARF DRIVE - NEW HAVEN,CT 06511 USA ph: 475-238-6837 fax: - jmohite@theruthgroup.com http://www.bioxceltherapeutics.com

• General Corporate Information    Officers Vimal Mehta - Chief Executive Officer and President Peter Mueller - Chairman Richard Steinhart - Chief Financial Officer June Bray - Director Sandeep Laumas - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 09075P105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/09/22 Share - Related Items Shares Outstanding: 27.99 Most Recent Split Date: (:1) Beta: 1.31 Market Capitalization: $379.76 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.27 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.78 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/09/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.96 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -3.70% vs. Previous Quarter: -20.43% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -48.25 12/31/21 - -46.42 09/30/21 - -44.97 ROA 03/31/22 - -45.13 12/31/21 - -43.54 09/30/21 - -42.33 Current Ratio 03/31/22 - 12.98 12/31/21 - 14.21 09/30/21 - 17.60 Quick Ratio 03/31/22 - 12.93 12/31/21 - 14.21 09/30/21 - 17.60 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 6.93 12/31/21 - 7.92 09/30/21 - 8.78 Inventory Turnover 03/31/22 - 0.00 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©